Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for Intellia Therapeutics (NTLA) over the last 11 years, with Q3 2025 value amounting to $343.3 million.

  • Intellia Therapeutics' Non-Current Assets fell 2575.74% to $343.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 billion, marking a year-over-year increase of 998.36%. This contributed to the annual value of $551.2 million for FY2024, which is 8211.05% up from last year.
  • Latest data reveals that Intellia Therapeutics reported Non-Current Assets of $343.3 million as of Q3 2025, which was down 2575.74% from $402.9 million recorded in Q2 2025.
  • In the past 5 years, Intellia Therapeutics' Non-Current Assets registered a high of $551.2 million during Q4 2024, and its lowest value of $115.8 million during Q1 2021.
  • For the 5-year period, Intellia Therapeutics' Non-Current Assets averaged around $360.5 million, with its median value being $375.5 million (2024).
  • Its Non-Current Assets has fluctuated over the past 5 years, first skyrocketed by 112961.12% in 2021, then crashed by 5664.81% in 2022.
  • Over the past 5 years, Intellia Therapeutics' Non-Current Assets (Quarter) stood at $525.2 million in 2021, then plummeted by 42.24% to $303.3 million in 2022, then dropped by 0.22% to $302.6 million in 2023, then surged by 82.11% to $551.2 million in 2024, then tumbled by 37.71% to $343.3 million in 2025.
  • Its last three reported values are $343.3 million in Q3 2025, $402.9 million for Q2 2025, and $434.8 million during Q1 2025.